approval
saveBALVERSA (ERDAFITINIB) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalBALVERSA (ERDAFITINIB) — FDA approvalOct 17, 2025 · 359d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalJan 19, 2024 · 996d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalJan 19, 2024 · 996d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalJan 19, 2024 · 996d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalMar 20, 2023 · 1301d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalJan 11, 2023 · 1369d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalApr 27, 2022 · 1628d ago
- approvalBALVERSA (ERDAFITINIB) — FDA approvalApr 27, 2022 · 1628d ago
same company · ±60 days · 6
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 19, 2024
- approvalguselkumab: TREMFYA (GUSELKUMAB) — FDA approvalSep 11, 2024
- approvalustekinumab: STELARA (USTEKINUMAB) — FDA approvalNov 15, 2024
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalNov 22, 2024
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalAug 19, 2024
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024
comments(0)
5-min edit window · permanent after that